Tempus ECG-AF vs FibriCheck
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your clinical practice aims to proactively identify patients aged 65 or older, without pre-existing AF, who are at an increased risk of developing atrial fibrillation within the next 12 months. This tool is ideal for integrating into existing cardiology workflows to leverage standard 12-lead ECG data for early risk stratification and targeted follow-up in a clinical setting.
View Tempus ECG-AF →Choose FibriCheck if…
Choose FibriCheck if you require a patient-centric, remote monitoring solution for individuals to regularly check their heart rhythm and detect arrhythmias using their smartphone. This tool is best suited for empowering patients to self-monitor at home, providing immediate results and enabling healthcare providers to remotely track and manage patients with suspected or diagnosed arrhythmias.
View FibriCheck →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | FibriCheck |
|---|---|---|
| Pricing | Contact vendor | Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer. |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based (private cloud). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FibriCheckFibriCheck is designed as a patient-facing mobile application, leveraging smartphone cameras for heart rhythm monitoring, making it highly accessible and user-friendly for individuals. Tempus ECG-AF, while integrated into healthcare systems, is a software solution primarily for use by healthcare professionals within a clinical setting, requiring specialized ECG equipment.
Clinical Value
Tempus ECG-AFTempus ECG-AF provides predictive clinical value by identifying patients at increased risk of developing AF within 12 months using a 12-lead ECG, enabling proactive intervention. While FibriCheck offers valuable real-time detection and monitoring of existing arrhythmias via a smartphone, Tempus's FDA-cleared predictive capability for a specific high-risk population using a gold-standard diagnostic offers a distinct and potentially higher impact clinical utility in early disease management.
Pricing & Value
Tempus ECG-AFTempus ECG-AF, while requiring vendor contact for direct pricing, has established CMS reimbursement codes (CPT 0764T and CPT 0765T) with a Medicare rate of $128.90, effective January 1, 2025, which provides a clear financial pathway for healthcare facilities. FibriCheck offers transparent subscription pricing for end-users and short-term prescriptions, but the established reimbursement for Tempus ECG-AF offers a more direct and significant value proposition for healthcare providers in terms of financial viability and integration into existing billing structures.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF explicitly states it is a 'Software solution, integrated into healthcare facility systems' and confirms BAA and HIPAA compliance, along with FDA clearance, demonstrating a strong focus on enterprise deployment and regulatory adherence. While FibriCheck also mentions HIPAA compliance and FDA clearance and offers a professional portal, Tempus's emphasis on deep integration into existing clinical workflows and explicit BAA makes it slightly more robust for enterprise readiness.
Innovation
FibriCheckFibriCheck demonstrates significant innovation by democratizing heart rhythm monitoring through a medically certified smartphone application that uses the device's camera. This approach makes advanced cardiac screening highly accessible to a broad patient population for remote monitoring. Tempus ECG-AF's innovation lies in its AI-driven *prediction* of future AF risk from standard ECGs, which is valuable, but FibriCheck's leverage of ubiquitous consumer technology for medical-grade monitoring is arguably more disruptive in terms of patient empowerment and accessibility.
Support & Docs
FibriCheckFibriCheck offers a comprehensive Help Center with user manuals for both patients and healthcare providers, along with clear contact information for support and developer documentation for integration. Tempus ECG-AF provides a direct support contact, but its public-facing, structured documentation appears less extensive and readily available compared to FibriCheck's multi-faceted support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | FibriCheck |
|---|---|---|
| Tool Name | Tempus ECG-AF | FibriCheck |
| Company | Tempus AI, Inc. | Qompium nv |
| Detection Method/Technology | AI-based algorithm for 12-lead ECG analysis | Smartphone camera-based PPG technology with AI-powered algorithm |
| Primary Use/Detection | Identifies patients aged 65 or older at increased risk of developing new onset Atrial Fibrillation (AF) within 12 months | Helps patients monitor their heart rhythm to detect and monitor Atrial Fibrillation (AFib) and other arrhythmias |
| Intended Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery | Patients needing heart rhythm monitoring |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and FibriCheck.